Neurology
Partner With Us
Advertisement
Conexiant chevron_right Neurology chevron_right Switching Anticoagulants After Breakthrough Stroke May Not Improve Outcomes
From the Journals

Switching Anticoagulants After Breakthrough Stroke May Not Improve Outcomes

Registry-based analysis found no short-term advantage to changing therapy following ischemic stroke in patients with atrial fibrillation

Conexiant
article Full Article subject Summary summarize Notecard
  • No short-term benefit to switching: Switching anticoagulants did not improve 90-day net clinical outcomes vs continuing the same DOAC.
  • Event rates were similar: Recurrent stroke and bleeding rates were low and comparable between strategies (~5% composite outcome).
  • Noninferiority achieved for most outcomes: Continuation met noninferiority criteria for net clinical benefit and key safety outcomes.
  • Mortality findings inconclusive: Noninferiority was not demonstrated for all-cause or vascular mortality, largely due to wide confidence intervals.
  • Switching strategy type did not matter: Outcomes were similar regardless of whether patients switched within DOAC class or to a different mechanism.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.